Paper20089952
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L and 11 others. N Engl J Med, 2010. Cited by 2,076 papers, by iCite.
Cite this record
ConductScience Library. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Papers, record 20089952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20089952
- Disease
- multiple sclerosis symptom measurement279 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunosuppressive Agents | Major topic |
| Multiple Sclerosis, Relapsing-Remitting | Major topic |
| Propylene Glycols | Major topic |
| Sphingosine | Major topic |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Arrhythmias, Cardiac | |
| Brain | |
| Disability Evaluation | |
| Disease Progression | |
| Double-Blind Method | |
| Female | |
| Fingolimod Hydrochloride | |
| Herpesviridae Infections | |
| Humans | |
| Kaplan-Meier Estimate | |
| Liver Function Tests | |
| Macular Edema | |
| Magnetic Resonance Imaging | |
| Male | |
| Middle Aged | |
| Young Adult |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00289978 | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02939079 | Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients | Background | ClinicalTrials.gov | |
| NCT03345940 | Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis | Background | ClinicalTrials.gov | |
| NCT04088630 | Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage | Background | ClinicalTrials.gov |
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 20089958 | Oral therapy for multiple sclerosis--sea change or incremental step? | https://conductscience.org/library/papers/20089958 | PubMed |
| Comment in | 20408749 | Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. | https://conductscience.org/library/papers/20408749 | PubMed |
| Comment in | 20445188 | Oral cladribine and fingolimod for relapsing multiple sclerosis. | https://conductscience.org/library/papers/20445188 | PubMed |
| Comment in | 20479024 | ACP Journal Club. Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis. | https://conductscience.org/library/papers/20479024 | PubMed |
| Comment in | 20574638 | Oral disease-modifying therapies for multiple sclerosis: are we there yet? | https://conductscience.org/library/papers/20574638 | PubMed |
Cited by1,097
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,076 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953005 | Exploring immune-endothelial interactions in neuroinflammation and vascular dysfunction. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42953005 | PubMed |
| 42947850 | Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications. | Front Neurol | 2026 | https://conductscience.org/library/papers/42947850 | PubMed |
| 42930009 | From Global Evidence to Saudi Practice: A Structured Evidence Map of the Diagnosis, Molecular Targets, and Therapeutic Strategies of Multiple Sclerosis in the Kingdom of Saudi Arabia. | Diseases | 2026 | https://conductscience.org/library/papers/42930009 | PubMed |
| 42930003 | Hypertension in People with Multiple Sclerosis: Epidemiology, Mechanisms, Hypertensive Disorders of Pregnancy, and Clinical Implications. | Diseases | 2026 | https://conductscience.org/library/papers/42930003 | PubMed |
| 42859599 | Small Molecule Therapeutic Approaches With a Greater Focus on Hearing Loss: A Review. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42859599 | PubMed |
| 42856682 | Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42856682 | PubMed |
| 42847050 | AI-enabled clinical trials. | Nat Rev Bioeng | 2026 | https://conductscience.org/library/papers/42847050 | PubMed |
| 42796323 | Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42796323 | PubMed |
| 42769928 | Evolving role of CD8+ tissue-resident memory T cells in autoimmune and immune mediated inflammatory diseases: linking pathogenesis to therapeutic approaches. | Front Immunol | 2026 | https://conductscience.org/library/papers/42769928 | PubMed |
| 42688580 | Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/42688580 | PubMed |
| 42687918 | Detection of Lipid-Mediated Diffused Pathological Changes in Multiple Sclerosis. | Res Sq | 2026 | https://conductscience.org/library/papers/42687918 | PubMed |
| 42682484 | Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42682484 | PubMed |
| 42579606 | Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. | Health Technol Assess | 2026 | https://conductscience.org/library/papers/42579606 | PubMed |
| 42548876 | Association between peripheral blood T cell subsets and clinical disability in multiple sclerosis patients. | Front Neurol | 2026 | https://conductscience.org/library/papers/42548876 | PubMed |
| 42474734 | Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review. | J Neurol | 2026 | https://conductscience.org/library/papers/42474734 | PubMed |
| 42462178 | The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2026 | https://conductscience.org/library/papers/42462178 | PubMed |
| 42432671 | The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42432671 | PubMed |
| 42364069 | Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42364069 | PubMed |
| 42329496 | Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases. | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/42329496 | PubMed |
| 42310690 | Higher disease reactivation risk in women after fingolimod withdrawal. | Acta Neuropathol Commun | 2026 | https://conductscience.org/library/papers/42310690 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| FINGOLIMOD | CHEMBL314854 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL314854 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20089952
GET https://conductscience.org/api/papers/v1/20089952/cited_by?page=2